P Pu ur rp po os se e: : To examine whether inhibition of P-glycoprotein (P-gp) activity by quinidine affects the central nervous system toxicity of lidocaine and racemic bupivacaine (bupivacaine).
M Me et th ho od ds s: : Forty male Sprague-Dawley rats were randomly divided into four groups (n = 10). Fifteen minutes following administration of 15 mg·kg ) was infused until convulsions occurred. Concentrations of lidocaine and its primary metabolite, monoethylglycinexylidide (MEGX) and bupivacaine in plasma and in the brain at the onset of convulsions were measured by high-performance liquid chromatography.
R Re es su ul lt ts s: : There were no differences in the dose of lidocaine required to induce convulsions between the L and QL groups. There were no differences in the concentrations of total (L = 17.2 ± 3.5, QL = 16.6 ± 2.6 µg·mL ) in plasma, total lidocaine or MEGX in the brain at the onset of convulsions between the L and QL groups. The dose of bupivacaine required to induce convulsions was comparable in the B and QB groups. At the onset of convulsions, plasma concentrations of both total (B = 4.9 ± 1.1, QB = 4.0 ± 0.6 µg·mL -1 , P = 0.03) and unbound bupivacaine (B = 1.4 ± 0.6, QB = 0.9 ± 0.2 µg·mL -1 , P = 0.02) were significantly lower in the QB group than in the B group. There were no differences in concentration of total bupivacaine in the brain between the B and QB groups.
C Co on nc cl lu us si io on n: : These results suggest that quinidine inhibited P-gp activity, resulting in increased brain/plasma concentration ratio of bupivacaine, but not of lidocaine, and decreased the threshold of plasma concentration for bupivacaine-induced convulsions. OCAL anesthetics are commonly used for regional anesthesia and treatment of arrhythmia. Accidental intravascular injection of a toxic dose of local anesthetics produces central nervous system (CNS) side effects such as dizziness, tremor and convulsions followed by cardiovascular collapse. 1 To induce CNS toxicity, local anesthetics must diffuse into the brain across the blood brain barrier. Previous studies have shown that influx of globulinbound as well as free lidocaine into the brain is not prevented by the blood brain barrier. 2 However, the blood brain barrier permeability of bupivacaine, a widely used long-acting local anesthetic with high lipid solubility and more than 90% protein binding, has not been examined.
Objectif : Vérifier si l'inhibition de l'activité des P-glycoprotéines (P-
The efflux pump P-glycoprotein (P-gp), a member of the adenosine triphosphate-binding cassette superfamily, was first identified in tumour cells by its ability to confer drug resistance to chemotherapeutic agents. 3 P-gp is found in various normal tissues including intestinal epithelium, liver canaliculi, renal tubules and bronchial epithelium. 4 Importantly, P-gp is a vital component of the blood brain barrier capable of actively pumping a variety of drugs out of the CNS. 5 Drugs transported by P-gp vary widely in structure. Relatively hydrophobic and amphipathic drugs, such as anticancer agents, steroid hormones, and calcium channel blocking agents, have been identified as P-gp substrates. 4 Although the common structural feature of substrate compounds and the mechanism by which P-gp can recognize such diverse substrates are not fully understood, striking overlap of the substrates for cytochrome P450 (CYP) 3A and P-gp, and of their tissue distribution, has been observed, possibly due to coordinate regulation of CYP3A and P-gp gene expression. 6 Amide-type local anesthetics including lidocaine, ropivacaine and bupivacaine are metabolized by CYP3A, [7] [8] [9] suggesting that Pgp might inhibit the expression of CNS toxicity of these local anesthetics by preventing the increase of their concentration in the brain.
Several drugs affect the CNS toxicity of local anesthetics. 10, 11 However, the effects of P-gp inducers or inhibitors on the CNS toxicity of local anesthetics remain unclear. Since local anesthetics are often used in combination with P-gp inhibitors such as verapamil, quinidine and cyclosporine, [12] [13] [14] examining the effect of P-gp inhibitors on the CNS toxicity of local anesthetics is important. In this study, we examined whether quinidine affects lidocaine-and bupivacaineinduced convulsions.
M Ma at te er ri ia al l a an nd d m me et th ho od ds s Experimental procedure
Following approval from the Institutional Animal Care and Use Committee, 40 male Sprague-Dawley rats aged nine weeks and weighing 320-360 g (CLEA Japan, Inc. Tokyo, Japan) were included in the study. Under general anesthesia with sevoflurane, the carotid artery was cannulated with a polyethylene catheter (PE 50, Becton Dickinson, Sparks, MD, USA) to monitor mean arterial blood pressure (MAP) and heart rate (HR) and for blood sampling. The cervical and femoral veins were cannulated with polyethylene catheters (SP31, Natsume, Tokyo, Japan) for infusion of drugs. These catheters were tunnelled subcutaneously to the posterior cervical region so that the animals could move freely. Before emergence from anesthesia, the animals were placed in a plastic container to recover for at least four hours before the experiment. Rectal temperature was maintained at 37°C with an infrared lamp. During that time, the arterial catheter was connected to a pressure transducer, and MAP and HR were recorded continuously on a polygraph (RM-6000, Nihon Kohden, Tokyo, Japan) connected to a computer. HR was monitored with a cardiotachometer triggered by the arterial pressure. The animals were randomly (by opening a sealed envelope) divided into lidocaine (L), quinidine and lidocaine (QL), bupivacaine (B), and quinidine and bupivacaine (QB) groups (n = 10, each group). Fifteen minutes after the iv injection of quinidine (15 mg·kg -1 , QL and QB groups) or the corresponding volume of saline (L and B groups), lidocaine (L and QL groups, 4 mg·kg -1 ·min -1 ) or racemic bupivacaine (bupivacaine, B and QB groups, 1 mg·kg -1 ·min -1 ) was infused intravenously by an infusion pump (Model 1235, Atom, Tokyo, Japan) until convulsions occurred. The dose of quinidine to inhibit P-gp activity was determined based on a previous report.
14 A bolus dose of ephedrine (10 µg, QL and QB groups) or corresponding volume of saline (L and B groups) was infused immediately after administration of quinidine, followed by a continuous infusion of ephedrine (10 µg·min -1 , QL and QB groups) or the corresponding volume of saline (L and B groups) to maintain MAP in the QL and QB groups at the same levels as in the L and B groups, respectively. In our preliminary study, neither 15 mg·kg -1 of quinidine nor 10 µg of bolus ephedrine followed by a continuous infusion of 10 µg·min -1 induced convulsions. Observation of rats Arterial blood (0.3 mL) was drawn before infusion of saline or quinidine (baseline), before infusion of lidocaine or bupivacaine and at the onset of convulsions to determine blood gas tensions, pH and serum potassium levels. An additional 0.3 mL of blood was obtained in QL and QB groups before the infusion of lidocaine or bupivacaine to determine the plasma concentration of quinidine. At the onset of convulsions, an additional 0.5 mL of blood was obtained to measure the plasma concentrations of lidocaine and monoethylglycinexylidide (MEGX), a principal metabolite of lidocaine, or bupivacaine, immediately followed by the iv infusion of pentobarbital (100 mg·kg -1 ) for euthanasia. The brain was perfused with 40 mL of ice-cold saline via a catheter inserted in the thoracic aorta and removed. Homogenate was made from the whole brain of each rat to determine the concentrations of lidocaine and MEGX or bupivacaine. Blood gas and electrolyte levels were measured immediately after sampling with a blood gas analyzer (ABL4, Radiometer, Copenhagen, Denmark). Remaining blood samples were centrifuged and plasma and brain samples were frozen and kept at -80°C until analysis. Plasma concentrations of quinidine were measured by fluorescent polarization immunoassay (FLX, Abbott Laboratories, Abbott Park, IL, USA).
Measurement of lidocaine, MEGX and bupivacaine in plasma and brain
Plasma concentrations of total (protein-bound and unbound) lidocaine, MEGX and bupivacaine were determined by high-performance liquid chromatography (HPLC). Briefly, ropivacaine, an internal standard, and Na 2 CO 3 and ethyl acetate were added to 150 µL of plasma, vortexed and centrifuged. The supernatant was transferred to another tube containing H 2 SO 4 , vortexed and centrifuged. The aqueous layer was discarded and the residue was mixed with NaOH and evaporated to dryness. HPLC was carried out as described previously. 15 Plasma concentrations of unbound lidocaine, MEGX and bupivacaine were measured using an ultrafiltration system (Centricon YM-30, Amicon, Inc., Beverly, MA, USA). Concentrations of local anesthetics in the brain were measured following the method of Yokoyama et al. 10 Regression coefficients of the calibration curves for lidocaine, MEGX and bupivacaine in plasma and brain were above 0.99. The lower limits of quantitation were 1, 0.1, and 0. tissue for lidocaine, MEGX and bupivacaine in the brain. Intra-assay and inter-assay variations were less than 7% throughout the range of testing. Concentrations of lidocaine, MEGX and bupivacaine in plasma were the mean of duplicate measurements. Brain concentrations were the mean of triplicate measurements. All values are expressed as mean ± standard deviation. Statistical analysis was performed using StatView 5.0 (SAS Institute Inc. Cary, NC, USA). The number of animals in each of the four groups was determined based on our preliminary data in ten animals. We assumed that a 30% decrease of the plasma concentration of local anesthetic at the onset of convulsions would be important. Assuming a type I error protection of 0.05 and a power of 0.80, nine to 11 animals in each group were required. Differences in convulsant doses of lidocaine or bupivacaine, concentrations of lidocaine, MEGX and bupivacaine in plasma and in the brain between the L and QL and B and QB groups were tested using an unpaired t test. Two-way analysis of variance (ANOVA) for repeated measures was used to compare MAP, HR, arterial blood gas and plasma potassium levels before infusion of local anesthetics and at the onset of convulsions with baseline values within groups and corresponding values in the L and QL and B and QB groups. Where a post hoc test was used, Bonferroni correction was applied. Values were considered significant when P < 0.05. R Re es su ul lt ts s The data set was complete for each rat entered in the study. There were no within group differences in arterial blood pH in either the L or QL groups, although pH at the onset of convulsions in the QL group was higher than in the L group (7.47 ± 0.05 vs 7.44 ± 0.03, respectively, P < 0.05). There were no differences in PaCO 2 at the onset of convulsions between the L and QL groups. PaO 2 , HCO 3 -or potassium levels were within normal limits in both the L and QL groups during experiments. MAP was stable and there were no differences in MAP at baseline, before infusion of lidocaine, or at the onset of convulsions in either the L or QL groups. Plasma concentration of quinidine at the beginning of infusion of lidocaine was 1.7 ± 0.5 µg·mL -1 in the QL group. There were no differences in the cumulative doses of lidocaine required to induce convulsions between the L and QL groups (31.6 ± 6.0 and 34.8 ± 7.3 mg·kg -1 , respectively). There were no differences in concentrations of total and unbound lidocaine in plasma or total lidocaine in the brain between the L and QL groups (Figure 1 ). There were no differences in the concentration of total and unbound MEGX in plasma or total MEGX in the brain between these two groups either (Figure 2) . The brain/plasma concentration ratios of total lidocaine at the onset of convulsions in the L and QL groups were 2.8 ± 1.0 and 2.3 ± 0.9, respectively (P > 0.05). The brain/plasma concentration ratios of total MEGX at the onset of convulsions in the L and QL groups were 1.9 ± 0.5 and 1.7 ± 0.6, respectively (P > 0.05).
Arterial blood pH at the onset of convulsions was significantly higher than baseline and before infusion of bupivacaine in both the B (7.48 ± 0.03, 7.44 ± 0.02, and 7.44 ± 0.03, respectively, P < 0.05) and QB (7.51 ± 0.03, 7.44 ± 0.04, and 7.47 ± 0.03, respectively, P < 0.05) groups. Also PaCO 2 at the onset of convulsions was significantly lower than baseline and before infusion of bupivacaine in both the B (27.8 ± 2.8, 34.9 ± 2.7, and 32.5 ± 2.6, respectively, P < 0.05) and QB (27.8 ± 3.9, 34.8 ± 2.8, and 33.0 ± 4.4, respectively, P < 0.05) groups. However there were no differences in pH or PaCO 2 between these two groups during the experiments. PaO 2 , HCO 3 -or potassium levels were within normal limits in both the B and QB groups during the experiments. MAP was increased by the infusion of bupivacaine. MAP at the onset of convulsions was significantly higher than baseline and before infusion of bupivacaine in both the B (155 ± 10, 101 ± 12, and 109 ± 10, respectively, P < 0.05) and QB (150 ± 10, 109 ± 11, and 110 ± 9, respectively, P < 0.05) groups. However there were no differences in MAP between these two groups during the experiments. The plasma concentration of quinidine at the beginning of infusion of bupivacaine was 1.7 ± 0.2 µg·mL -1 in the QB group, which was comparable to the value in the QL group. There were no differences in the cumulative doses of bupivacaine required to induce convulsions between the B and QB groups (7.2 ± 2.2 vs 8.8 ± 1.6 mg·kg -1 , respectively). Plasma concentrations of both total and unbound bupivacaine were significantly lower in the QB group than in the B group at the onset of convulsions (P = 0.03 and 0.02, respectively; Figure  3 ). There were no differences in brain concentration of total bupivacaine between the B and QB groups (Figure 3) . The brain/plasma concentration ratios of total bupivacaine in the QB group were significantly higher than those in the B group (3.4 ± 1.0 vs 2.5 ± 0.6, respectively, P = 0.02). In the present study, 2,6-pipecoloxylidide, an active metabolite of bupivacaine, 16 was not detected in plasma or in the brain. D Di is sc cu us ss si io on n In the present study, quinidine reduced the plasma concentration and increased the brain/plasma concentration ratio of bupivacaine at the onset of convulsions. Since quinidine inhibits P-gp activity at plasma concentrations lower than those used in the present study, 13, 14 our results suggest that bupivacaine may be a substrate of P-gp and that inhibition of P-gp by quinidine increased the concentration of bupivacaine in the brain and reduced the plasma concentration of bupivacaine required to induce convulsions. Increased brain/plasma concentration ratio of P-gp substrates as observed in our study has also been reported in mice lacking P-gp compared with wild mice and in animals receiving P-gp inhibitors compared with those without P-gp inhibitors. 5, 17 However, in vitro studies directly showing more accumulation of bupivacaine in cells expressing P-gp than in cells lacking P-gp and/or showing specific binding of bupivacaine to membrane of P-gp-expressing cells, which is reversed by P-gp inhibitor, 18 will be required to conclude that bupivacaine is a substrate of P-gp.
The CNS toxicity of local anesthetics is influenced by various conditions, such as rate of injection of drugs, MAP, blood pH and PaCO 2. 10,19,20 In the present study, blood gas data and MAP were comparable between the L and QL and between the B and QB groups, suggesting that MAP and blood gases had little effect on our results. The convulsive doses and plasma concentrations of bupivacaine at the onset of convulsions were comparable to those noted in a previous report. 21 The brain/plasma concentration ratio of bupivacaine in the B group at the onset of convulsions was also comparable to that reported by Morishima et al. 22 Despite the lower plasma concentration of bupivacaine in the QB group than in the B group at the onset of convulsions, the cumulative doses of bupivacaine required to induce convulsions were comparable in these two groups. Although the reason for this discordance in our findings is not clear, ephedrine may have increased cardiac output, resulting in the increased hepatic blood flow and systemic clearance of bupivacaine. The other possible reason is the increased volume of distribution of bupivacaine by quinidine or ephedrine, which may alter its pharmacokinetics. 23 Quinidine may also affect the protein binding of bupivacaine. However, plasma concentrations of unbound as well as total bupivacaine were lower in the QB group than in the B group at the onset of convulsions, suggesting that alteration of protein binding of bupivacaine did not account for the decreased threshold of plasma concentration for induction of convulsions.
In contrast to bupivacaine, quinidine had no effect on the convulsive dose or concentrations of lidocaine in plasma or brain at the onset of convulsions. Pardridge et al. 2 showed that influx of lidocaine to the brain is not restricted by the blood brain barrier. Pajeva et al. 24 also reported that lidocaine does not interact with phospholipids constructing tumour cells expressing P-gp. The results of the present study are consistent with these reports. The convulsive dose of lidocaine and the plasma and brain concentrations of lidocaine at the onset of convulsions were similar to those reported previously. 10, 11 There were no differences in the concentration of MEGX, a principal metabolite of lidocaine with convulsive potency, 25 in plasma or brain between the L and QL groups, either.
Various agents such as calcium channel blockers, coronary vasodilators, quinolines, and cyclosporine have P-gp inhibitory activity. 4 Of these inhibitors, we used quinidine, since it is often administered chronically for the treatment of arrhythmia and patients receiving quinidine can be given local anesthetics. Although quinidine may decrease MAP and HR, it had no effect on MAP when administered in combination with ephedrine in our experiments. Verapamil and cyclosporine are often used as P-gp inhibitors. However, these agents are also substrates of P-gp and inhibit P-gp activity in a competitive manner, 26, 27 suggesting that the degree of inhibition of P-gp depends on the concentration ratio of inhibitors and substrates. The concentrations of these inhibitors required to inhibit P-gp-dependent transport of local anesthetics are unknown, since no data are available regarding the inhibition constants of these inhibitors. Rifampin, an inducer of P-gp may affect the CNS toxicity of bupivacaine, However, rifampin also induces CYP3A, an enzyme responsible for the metabolism of bupivacaine, 9 might affect the convulsive dose and plasma concentration for inducing convulsions of bupivacaine by increasing the systemic clearance.
In spite of a large number of reports describing the CNS toxicity of bupivacaine in the clinical setting, 28 very little information is available regarding the plasma concentration of bupivacaine at the onset of CNS toxicity. Baaijens et al. 29 reported that the plasma concentrations of total and free bupivacaine in a patient who developed convulsions during cervical epidural analgesia were 6.7 and 1.2 µg·mL -1 , respectively, which are comparable to our results. Obviously, the results of the present study cannot be extrapolated directly to humans. However, the inhibition of P-gp by quinidine results in respiratory depression by loperamide, which is absent without quinidine, 12 suggesting that the CNS effects of clinically used P-gp substrates is enhanced by P-gp inhibitors.
In summary, we showed that quinidine reduced the plasma concentration threshold for bupivacaineinduced, but not lidocaine-induced, convulsions in awake rats. Since quinidine is a P-gp inhibitor in humans as well as in animals, our results suggest that the CNS toxicity of bupivacaine should be monitored carefully when a drug with P-gp inhibition activity is used in combination with bupivacaine.
